Long-term maintenance of functional primary human hepatocytes using small molecules

FEBS Lett. 2020 Jan;594(1):114-125. doi: 10.1002/1873-3468.13582. Epub 2019 Aug 30.

Abstract

The immediate deterioration of primary human hepatocytes (PHHs) during culture limits their utility in drug discovery studies. Here, we report that a cocktail of four small molecule signaling inhibitors, termed YPAC, is useful for maintaining various hepatic functions of PHHs, including albumin and urea productivity, glycogen storage, and cytochrome P450 (CYP) expression. Most importantly, we found that YPAC allows PHHs to retain enzymatic activities of CYP1A2, CYP2B6, and CYP3A4 even after 40 days of culture, and that inducibility of CYP3A4 activity in response to the prototypical inducers rifampicin and phenobarbital is also maintained. Our novel approach could facilitate drug discovery studies.

Keywords: cytochrome P450; drug discovery; epithelial-mesenchymal transition; hepatocytes; long-term cell culture; small molecule inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amides / pharmacology*
  • Cell Proliferation
  • Cells, Cultured
  • Cytochrome P-450 Enzyme System / genetics
  • Cytochrome P-450 Enzyme System / metabolism
  • Glycogen / metabolism
  • Hepatocytes / drug effects*
  • Hepatocytes / metabolism
  • Hepatocytes / physiology
  • Humans
  • Phenobarbital / pharmacology
  • Primary Cell Culture / methods*
  • Protein Kinase Inhibitors / pharmacology*
  • Pyridines / pharmacology*
  • Pyrimidines / pharmacology*
  • Rifampin / pharmacology
  • Urea / metabolism

Substances

  • Amides
  • Chir 99021
  • Protein Kinase Inhibitors
  • Pyridines
  • Pyrimidines
  • Y 27632
  • Urea
  • Glycogen
  • Cytochrome P-450 Enzyme System
  • Rifampin
  • Phenobarbital